EMA's March verdict on domperidone will consider Prescrire's "sudden death" claims
This article was originally published in Scrip
Executive Summary
The European Medicines Agency, whose pharmacovigilance risk assessment committee (PRAC) is reviewing the safety of the anti-emetic drug domperidone, says the committee will consider claims by the French drug bulletin Prescrire that the product may have caused as many as 120 sudden deaths in France alone last year.